Print this page
-
A Phase II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers.
Protocol: 192204Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Other Male Genital
Larynx
Other Female Genital
Cervix
Anus
Lip, Oral Cavity and Pharynx -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
Biospecimen Procurement for Cancer Immunotherapy at Rutgers Cancer Institute.
Protocol: 192002Principal Investigator:
- Christian Hinrichs (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase 1, multicenter, open-label, 2-stage, single-arm study to evaluate the safety and tolerability of an autologous tumor-infiltrating lymphocytes (TIL) regimen and preliminary antitumor activity of TIL in pediatric, adolescent, and young adult participants with relapsed or refractory solid tumors
Protocol: 112309Principal Investigator:
- Niketa Shah MD (Robert Wood Johnson University Hospital, New Brunswick)
Applicable Disease Sites: Any Site -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403Principal Investigator:
- Dylan Roden (New Jersey Medical School)
Applicable Disease Sites: Lip, Oral Cavity and Pharynx